"Second Opinion" with Christina Farr, Ash Zenooz MD & Luba Greenwood JD
Breaking down biotech with Daphne Zohar: VC dynamics, drug development, and the Biosecure Act
Aug 7, 2024
Daphne Zohar, Founder and CEO of Seaport Therapeutics, shares her deep insights into the biotech landscape. She discusses the complex challenges of drug development, particularly in psychiatric treatments, while shedding light on high failure rates and funding obstacles. Daphne explores the intersection of tech and biotech investment, emphasizing the regulatory hurdles and the implications of the Biosecure Act on innovation. She advocates for greater transparency in the industry and the necessity of political support to drive progress in patient care.
40:21
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The integration of technology into drug commercialization can significantly improve patient accessibility and streamline biotech marketing efforts.
- Investments in mental health treatment are gaining momentum, driven by societal awareness and successful therapeutic innovations like Ozempic.
Deep dives
The Role of Technology in Drug Commercialization
The technology sector has significant potential to enhance the commercialization of pharmaceuticals, which is an area where traditional biotech and pharma companies often struggle. Tech companies possess strong skills in engaging with customers, while biotech firms typically lack this expertise and incur high costs to connect with their target markets. Leveraging technology in drug commercialization could streamline processes and improve accessibility for patients. The podcast discusses how integrating tech strategies could lead to more effective marketing and distribution of new drugs.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
